Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1236 Neoplasms 1040 Carcinoma, Non-Small-Cell Lung 861 Prostatic Neoplasms 692 Colorectal Neoplasms 614 Lung Neoplasms 578 Neoplasm Metastasis 439 Multiple Myeloma 425 Leukemia, Myeloid, Acute 401 Pancreatic Neoplasms 376 Ovarian Neoplasms 364 Melanoma 320 Carcinoma, Hepatocellular 288 Recurrence 276 Squamous Cell Carcinoma of Head and Neck 275 Brain Neoplasms 266 Glioblastoma 247 Head and Neck Neoplasms 244 Stomach Neoplasms 239 Carcinoma, Renal Cell 228 Precursor Cell Lymphoblastic Leukemia-Lymphoma 227 Lymphoma 225 Triple Negative Breast Neoplasms 219 Hematologic Neoplasms 209 Endometrial Neoplasms 209 Urinary Bladder Neoplasms 202 Lymphoma, Non-Hodgkin 197 Uterine Cervical Neoplasms 194 Sarcoma 190 Glioma 190

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ALK-positive NSCLC × 90 days × Clear all

NCT07491497 2026-05-07

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

TRIANA Biomedicines, Inc.

Phase 1/2 Recruiting

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡